Bioglutide; quadruple GLP agonist; oral form

[tommyguns2]

This is presently in Phase 2 trials. The 4th agonist targets IGF-1 to prevent muscle loss. I've used the semaglutide and retatrutide and haven't found them to be overly catabolic, but I suspect the research data is performed on general population obese people that are just losing weight and not also incorporating the drug with a bodybuilding diet and regular training.

Here's some ChatGPT info, as well as a Youtube and DDT podcast talking about it. The DDT podcast seems pretty interesting.

• Bioglutide is an investigational drug being developed by Biomed Industries, Inc., under the code name NA-931. EIN Presswire+3biomedind.com+3biomedind.com+3
• It is described as an oral, once‐daily compound (i.e., a pill), unlike many of the current GLP-1 / weight‐loss / metabolic drugs which are injections. biomedind.com+1
• The unique feature (according to the company) is that it is a “quadruple receptor agonist”: it supposedly targets four receptor systems — namely the GLP-1 receptor, GIP receptor, glucagon receptor, and the IGF-1 receptor. biomedind.com+2Fit Science Nutrition+2
• The intended uses: obesity, overweight with comorbidity, and potentially type 2 diabetes / metabolic disorders. biomedind.com+2biomedind.com+2

---

Mechanism & Potential Benefits​

• By targeting GLP-1, GIP, glucagon and IGF-1 receptors, the idea is to not only reduce appetite + slow gastric emptying (classic GLP-1 effect) but also increase energy expenditure (via glucagon), preserve muscle mass (via IGF-1), and improve insulin/glucose homeostasis (via GIP). biomedind.com+1
• The “oral” route is a big deal — convenience + better adherence compared to injections. The company claims fewer of the side‐effects typical for current GLP-1 therapies (nausea, vomiting, etc) while maintaining strong weight‐loss/metabolic effects. EIN Presswire
• Early claims: in Phase 2 (or Phase 2b) trials they reported substantial fat mass loss without muscle loss (as per company press releases). biomedind.com+1

---

Status & Limitations​

• Not yet approved for general use. It’s still in the clinical trial/development stage. biomedind.com+1
• Although the company claims good results, independent peer‐reviewed publications seem limited / not widely available (at least publicly).
• Some sources raise caution: e.g., research‐material suppliers identify “Bioglutide” as a “research material” and note it’s not approved for human use. LimitlessBioChem
• Online forums/reddit discussions highlight skepticism:
  

  “There’s growing evidence bioglutide is a scam… Not just aftermarket stuff…” Reddit
  “The molecular formula for the investigational drug NA-931 (also known as Bioglutide™) … is … unknown.” Reddit

• Because it’s investigational, safety, long‐term effects, optimal dosing, side effects in real world patients are not fully established.
• Oral bioavailability and effectiveness: With many drugs, especially “pill” vs injection, absorption, metabolism, real‐world effect may differ from ideal. Some of the hype may be ahead of full data.

---

Practical Implications​

• If you’re looking at this from a clinical/medical perspective: it’s a promising next‐generation metabolic drug, but it’s not something you can expect to be available or well‐vetted yet.
• If you’re considering it from a consumer/weight‐loss point of view: don’t rely on it as a current option — talk to your healthcare provider about approved therapies.
• Consider the hype vs evidence: new drugs often attract excitement but always need time for robust trials.
• Keep an eye on: When Phase 3 data are published, regulatory filings, approvals, side‐effect profiles, cost, availability.

---

Quick summary — what Bioglutide (NA-931) is

• Bioglutide (NA-931) is an investigational, oral metabolic drug developed by Biomed Industries. The company describes it as a “quadruple receptor agonist” (targets GLP-1, GIP, glucagon and IGF-1 receptors) intended for obesity and related metabolic disorders. It is not an approved medicine — it is in clinical trials. biomedind.com+1

Current clinical status (as of 2025)​

• Biomed reports completed Phase 2 work and has been advancing NA-931 into later-stage trials and conference presentations (ADA / EASD 2025 announcements / presentations). ClinicalTrials.gov lists trials studying NA-931 alone and in combination with tirzepatide. However, peer-reviewed, full Phase-2 datasets in high-impact journals are limited publicly as of these announcements — much of the detailed numeric data comes from company releases and conference abstracts. biomedind.com+1

How it might differ from current drugs​

• Route: oral pill (major convenience advantage if clinical efficacy & safety hold). biomedind.com
• Mechanism: company claims activity at four receptors (GLP-1, GIP, glucagon, IGF-1). If true, that combination aims to reduce appetite (GLP-1/GIP), increase energy expenditure (glucagon), and protect muscle (IGF-1). These are theoretical/intentional advantages and must be verified in large randomized trials. biomedind.com

Comparison with semaglutide and tirzepatide (real-world/clinical benchmarks)​

• Efficacy (weight loss, approximate, from large trials):
  • Semaglutide (Wegovy / Ozempic) — established injectable GLP-1. Typical trial results: ~15% mean weight loss over 68–72 weeks at the approved Wegovy dose (numbers vary by study and dose). Vox+1
  • Tirzepatide (Mounjaro / Zepbound) — GIP/GLP-1 dual agonist. In head-to-head and SURMOUNT results, mean weight loss has reached ~20% (varies by dose and trial). Recent major comparative data (2025) showed tirzepatide outperforming semaglutide on average weight loss. nejm.org+1
• Safety/tolerability: semaglutide and tirzepatide share similar GI adverse events (nausea, vomiting, diarrhea, constipation). Anticipated side effects for NA-931 will need to be confirmed — company statements claim favorable tolerability but independent, long-term safety data are not yet public. biomedind.com+1

Bottom line / practical takeaways​

1. Bioglutide (NA-931) is promising because it’s oral and claims a multi-receptor mechanism that could combine appetite suppression with increased energy expenditure and muscle preservation — but it’s still investigational. Public, peer-reviewed Phase-2/3 numeric results are limited and we should treat company press releases as preliminary until full published data are available. biomedind.com+1
2. Benchmarks to beat: semaglutide ≈ 15% weight loss (large trials) and tirzepatide ≈ ~20% (higher doses / certain trials). Any new oral drug will be judged against those effectiveness and safety standards. Vox+1

---

Would you like me to pull the specific Phase-2 numerical results / slides or the ClinicalTrials.gov trial pages for NA-931 now (I can extract the trial designs, endpoints, and any posted topline numbers), or would you prefer a concise side-by-side table of the three drugs with doses, trial durations, and typical side-effect rates?
​

I pulled the available Phase-2 / trial pages for Bioglutide (NA-931) and then placed the Phase-2 toplines beside comparable, well-published benchmarks for semaglutide and tirzepatide. I cite the original trial pages, conference abstracts and high-quality papers so you can inspect the sources.

---

1) Key Phase-2 / trial sources I pulled for NA-931 (Bioglutide)​

• Biomed Industries NA-931 summary / Phase-2 notices (company site). biomedind.com+1
• ClinicalTrials.gov listing for a Phase-2 study of NA-931 (and a combo study with tirzepatide). ClinicalTrials.gov
• Conference/abstract records (ADA / EASD / Diabetes supplement) reporting Phase-2 data and posters. Example abstracts: Diabetes supplement (Phase-2, 13-week MAD study) and EASD/ADA news items. diabetesjournals.org+1
• Press / meeting coverage summarizing topline Phase-2 numbers (company/meeting releases report up to ~13.8% weight loss and claims of muscle mass preservation). biomedind.com+1

Short interpretation: NA-931 is oral, once-daily, described by the company as a quadruple receptor agonist (GLP-1, GIP, glucagon, IGF-1). Phase-2 toplines reported in meeting abstracts / company releases indicate dose-dependent weight loss (examples cited up to ~13.8% in some cohorts), but full peer-reviewed Phase-2 publications are limited as of these releases — treat these as preliminary toplines. biomedind.com+1

---

2) Trial design / endpoints for NA-931 (what ClinicalTrials.gov shows)​

• Example Phase-2 entry (NCT06732245): randomized study investigating NA-931 ± tirzepatide, with endpoints including body-weight change, body-composition (fat vs muscle), and safety/tolerability. Trial types include MAD (multiple ascending dose) 13-week studies and longer randomized placebo-controlled arms. See ClinicalTrials.gov listing for design details and identifiers. ClinicalTrials.gov+1

---

3) Topline Phase-2 numeric results reported (NA-931)​

• Company / conference reporting (ADA / ENDO / EASD 2025 coverage) lists dose-dependent mean weight reductions and an example topline of up to ~13.8% mean weight loss (and a reported ~12.4% difference vs placebo in a cited cohort). These reports also emphasize no observed muscle mass loss in their body-composition assessments and generally mild/transient GI adverse events in Phase-2. These numbers are from meeting/press abstracts rather than full peer-reviewed papers. biomedind.com+1

Important: because the available NA-931 numeric results come from company/meeting abstracts, they are preliminary. Full methods, confidence intervals, exact dose groups, and safety breakdowns await peer-reviewed publication or full conference slides. diabetesjournals.org+1

---

4) Side-by-side concise table (doses, trial duration, typical mean weight loss, common side effects)​

Drug (typical marketed / trial dose)	Typical trial duration reported	Mean weight-loss (approx., trial)	Major, common adverse effects
Bioglutide (NA-931) — oral, once-daily (investigational; multiple doses tested)	Phase-2 reports at ~13 weeks (MAD) and longer randomized arms; Phase-2 → Phase-3 planning.	Reported Phase-2 toplines: up to ~13.8% mean weight reduction in some cohorts (company/meeting abstracts). Preliminary.	Company/abstracts: mild/transient GI (nausea/diarrhea), claims of muscle mass preservation; long-term safety not established. diabetesjournals.org+1
Semaglutide (Wegovy / Ozempic) — injectable GLP-1 (e.g., 2.4 mg weekly for obesity)	Major trials: 68–72 weeks (most pivotal trials ~68–72 wks; longer follow-ups published).	~14.9% mean at 68 weeks in STEP program (Wegovy; Wilding et al. NEJM). Newer high-dose data (7.2 mg) reported ~20.7% at 72 weeks (company/press 2025).	GI effects (nausea, vomiting, constipation, diarrhea); potential for gallbladder events, rare pancreatitis; increased heart rate observed. PubMed+1
Tirzepatide (Mounjaro / Zepbound) — injectable GIP/GLP-1 (5, 10, 15 mg weekly)	Major trials: 72 weeks (SURMOUNT / pivotal trials).	Reported mean weight loss ranges by dose; ~18–22% at 72 wks in major trials (higher doses → greater loss). Recent head-to-head trials show ~20% range.	GI adverse events common (nausea, diarrhea, vomiting); metabolic benefits (glucose); safety profile still being characterized in long term. nejm.org+1

(Numbers above are rounded trial averages from published trials and meeting reports; see citations for study-level detail.)

---

5) Short critical comparison / interpretation​

• Efficacy: Semaglutide and tirzepatide have robust, large randomized trial programs with peer-reviewed publications showing ~15% (semaglutide, standard dose) and ~18–22% (tirzepatide, depending on dose) mean weight loss at ~72 weeks. NA-931’s reported Phase-2 results (up to ~13.8%) are encouraging for an oral drug, but were measured over shorter windows and have limited publicly-available detail; it will be compared against the 72-week benchmarks as it progresses. PubMed+2nejm.org+2
• Safety & evidence depth: semaglutide and tirzepatide have large datasets and real-world experience; NA-931’s safety/tolerability looks acceptable in early trials per company/meeting reports, but we need full Phase-2 papers and Phase-3 data to judge long-term safety, rare events, and durability. diabetesjournals.org+1
• Practical difference: If NA-931’s oral efficacy and safety holds up in Phase-3, the oral route would be a significant practical advantage for many patients over weekly injections. But regulatory approval, pricing, and head-to-head efficacy vs the current best-in-class will determine real-world uptake.

https://www.audacy.com/podcast/ddt-method-podcast-060db/episodes/live-building-my-new-protocol-with-anthony-castore-pt-2-7d4c1